Cytokinetics (NASDAQ:CYTK) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a research note issued to investors on Tuesday,Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on CYTK. UBS Group reissued a “buy” rating and issued a $104.00 target price on shares of Cytokinetics in a report on Wednesday, October 14th. Citizens Jmp boosted their price target on Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Citigroup reiterated a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Barclays upped their price target on Cytokinetics from $95.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Finally, JPMorgan Chase & Co. increased their price objective on Cytokinetics from $97.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and an average target price of $105.44.

Cytokinetics Price Performance

Shares of Cytokinetics stock opened at $63.95 on Tuesday. The firm has a market capitalization of $7.96 billion, a PE ratio of -8.86 and a beta of 0.41. The company’s fifty day moving average price is $69.63 and its two-hundred day moving average price is $73.23. Cytokinetics has a 52-week low of $54.30 and a 52-week high of $88.31.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. Cytokinetics’s revenue was down 57.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.12) earnings per share. Analysts predict that Cytokinetics will post -5.98 earnings per share for the current fiscal year.

Insider Activity at Cytokinetics

In other Cytokinetics news, Director Robert Landry sold 1,000 shares of Cytokinetics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $72.13, for a total value of $72,130.00. Following the completion of the transaction, the director owned 8,184 shares in the company, valued at approximately $590,311.92. The trade was a 10.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the business’s stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $64.01, for a total value of $224,035.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares in the company, valued at approximately $9,851,267.02. This represents a 2.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 191,426 shares of company stock valued at $13,543,855 in the last three months. Corporate insiders own 2.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. boosted its stake in shares of Cytokinetics by 810.2% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 446 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 397 shares during the last quarter. Pinnacle Associates Ltd. raised its stake in shares of Cytokinetics by 6.7% during the third quarter. Pinnacle Associates Ltd. now owns 215,952 shares of the biopharmaceutical company’s stock worth $14,233,000 after buying an additional 13,512 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Cytokinetics by 2.7% during the third quarter. Nisa Investment Advisors LLC now owns 13,050 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 345 shares during the last quarter. AMI Asset Management Corp lifted its holdings in Cytokinetics by 3.8% in the third quarter. AMI Asset Management Corp now owns 14,800 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 539 shares during the period. Finally, V Square Quantitative Management LLC boosted its stake in Cytokinetics by 71.5% in the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 191 shares during the last quarter.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Health Canada approved MYQORZO (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III). The approval expands Cytokinetics’ international commercial opportunity and reinforces confidence in the drug’s regulatory and clinical profile. Health Canada approval announcement
• Positive Sentiment: Coverage highlighted growing MYQORZO prescriptions, international launches and encouraging clinical data, suggesting the product could become an increasingly important growth driver for Cytokinetics. MYQORZO growth analysis
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating with a $140 price target, implying substantial upside from recent trading levels and providing a bullish counterpoint to more cautious views. HC Wainwright rating report
• Neutral Sentiment: Cytokinetics granted options covering 60,465 shares and 40,084 restricted stock units to 29 recently hired employees as inducements. The grants support recruitment but may create modest future share dilution. Inducement grants announcement
• Negative Sentiment: BofA Securities lowered its price target to $81 from $85 while maintaining a Neutral rating, signaling less near-term conviction despite the target remaining above the recent share price. BofA price-target update
• Negative Sentiment: Wall Street Zen downgraded CYTK to Sell, adding to investor concerns about valuation, execution and the company’s continuing losses. Wall Street Zen rating downgrade
• Negative Sentiment: Executive Vice President Fady Malik sold 3,500 shares worth approximately $224,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan, reducing its signaling value, but still represents a modest insider-selling overhang. SEC insider transaction filing

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.